Journal of Medicinal Chemistry · 2001 · 79 citations · 2 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsAnalgesic PharmacologyEnzyme InhibitionHit-to-lead OptimizationInflammation PharmacologyAdenosine Monophosphate-activated Protein Kinase PathwayAnalgesic Anti-inflammatory PharmacologyAnimal Disease ModelsMetabolic Enzyme InhibitionNon-nucleoside InhibitorsPteridine ChemistryPyrimidine AnalogsPyrimidine Analogues
Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation. Inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC(50) = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC(50) = 1.7 nM) non-nucleoside AK inhibitor with oral activity in animal models of pain and inflammation.
2
Les P. Davies, Dana Jamieson, Judith Baird‐Lambert et al. · Biochemical Pharmacology · 1984 · 82 citations
Clitocine, a new insecticidal nucleoside from the mushroom clitocybe inversa
Isao Kubo, Mujo Kim, William F. Hood et al. · Tetrahedron Letters · 1986 · 63 citations